Adenocarcinoma of the Uterine Corpus

Clinical Gynecologic Oncology: Eighth Edition

Volumn , Issue , 2012, Pages 141-174

  Creasman, William T ^a   Miller, David Scott ^b  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84872105892     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-323-07419-3.00005-9     Document Type: Chapter

References (248)

1. American Cancer Society Cancer Facts and Figures 2010 2010, American Cancer Society, Atlanta.
2. Antunes CMF, Strolley PD, Rosenshein NB, et al. Endometrial cancer and estrogen use (report of a large case-control study). N Engl J Med 1979, 300:9.
3. Barakat RR The effects of tamoxifen on the endometrium. Oncology (Huntingt) 1995, 9:129.
4. Barakat RR, Eonf G, Curain JP Tamoxifen use in breast cancer patients who subsequently develop corpus cancer is not associated with a higher incidence of adverse histological features. Gynecol Oncol 1994, 55:164.
5. Beresford SA, Weiss NS, Voigt LF, McKnight B Risk of endometrial cancer in relation to use of oestrogen combined with cyclic progestogen therapy in postmenopausal women. Lancet 1997, 349:458.
6. Bokhman JV Two pathogenetic types of endometrial carcinoma. Gynecol Oncol 1983, 15:10.
7. Brinton LA, Berman ML, Mortel R, et al. Reproductive, menstrual, and medical risk factors for endometrial cancer: results from a case-control study. J Obstet Gynecol 1992, 167:1317.
8. Burstein HJ, Prestrud AA, Seidenfeld J, et al. American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer. J Clin Oncol 2010, 28:3784.
9. Creasman WT, Odicino F, Maisonneuve P, et al. Carcinoma of the corpus uteri. Int J Gynecol Obstet 2006, 95:S105.
10. Duffy SR, Distler W, Howell A, et al. A lower incidence of gynecologic adverse events and interventions with anastrozole than with tamoxifen in the ATAC trial. Am J Obstet Gynecol 2009, 200:80.e1.
11. Early Breast Cancer Trialists' Collaborative Group (EBCTCG) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005, 365:1687.
12. Elwood JM, Cole P, Rothman KJ, Kaplan SD Epidemiology of endometrial cancer. J Natl Cancer Inst 1977, 59:1055.
13. Evans-Metcalf ER, Brooks SE, Reale FR, Baker SP Profiles of women 45 years of age and younger with endometrial cancer. Obstet Gynecol 1998, 91:349.
14. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst 1998, 90:1371.
15. Fisher B, Costantino JP, Redmond CK, et al. Endometrial cancer in tamoxifen treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. J Natl Cancer Inst 1994, 86:527.
16. Gunter MJ, et al. A prospective evaluation of insulin and insulin-like growth factor-I as risk factors for endometrial cancer. Cancer Epidemiol Biomarkers Prev 2008, 17:921.
17. Hoover R, Fraumeni JF, Everson R, et al. Cancer of the uterine corpus after hormonal treatment for breast cancer. Lancet 1976, 1:885.
18. Kaku T, Matsumura M, Sakai K, et al. Endometrial carcinoma in women 65 years of age or older: a clinicopathologic study. Eur J Gynaecol 1996, 17:357.
19. Killackey MA, Hakes TB, Pierce VK Endometrial adenocarcinoma in breast cancer patients receiving antiestrogens. Cancer Treat Rep 1985, 69:273.
20. Lawrence C, et al. Smoking, body weight, and early stage endometrial cancer. Cancer 1987, 59:1665.
21. Levi F, Franeschi S, Negri E, LaVecchia C Dietary factors and the risk of endometrial cancer. Cancer 1993, 71:3775.
22. Lu KH, Dinh M, Kohlmann W, et al. Gynecologic cancer as a "sentinel cancer" for women with hereditary nonpolyposis colorectal cancer syndrome. Obstet Gynecol 2005, 105:569.
23. MacMahon B Risk factors for endometrial cancer. Gynecol Oncol 1974, 2:122.
24. MacMahon B Overview of studies on endometrial cancer and other types of cancer in humans: perspective of an epidemiologist. Semin Oncol 1997, 24:S1.
25. Magriples U, Naftolin F, Schwartz PE, et al. High grade endometrial carcinoma in tamoxifen treated breast cancer patients. J Clin Oncol 1993, 11:485.
26. Million Women Study Collaborators Endometrial cancer and hormone replacement therapy in the Million Women Study. Lancet 2005, 365:1543.
27. Novak E, Yui E Relationship of endometrial hyperplasia to adenocarcinoma of the endometrium. Am J Obstet Gynecol 1936, 32:674.
28. Nyholm NCV, Neilsen AL, Norup P Endometrial cancer in postmenopausal women with and without previous estrogen replacement treatment: comparison of clinical and histopathological characteristics. Gynecol Oncol 1993, 49:229.
29. Schapira DV, Kumar NB, Lyman GH, et al. Upper-body fat distribution and endometrial cancer risk. JAMA 1991, 266:1808.
30. Schmeler KM, et al. Prophylactic surgery to reduce the risk of gynecologic cancers in the Lynch syndrome. N Engl J Med 2006, 354:261.
31. Smith DC, et al. Association of exogenous estrogen and endometrial carcinoma. N Engl J Med 1975, 293:1164.
32. Smith IE, Dowsett M Aromatase inhibitors in breast cancer. N Engl J Med 2003, 348:2431.
33. Swanson CA, Potischman N, Wilbanks GD, et al. Relationship of endometrial cancer risk to past and contemporary body size and body fat distribution. Cancer Epidemiol Biomarkers Prev 1993, 2:321.
34. Veronesi U, Maisonneuve P, Costa A, et al. Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomised trial among hysterectomised women. Lancet 1998, 352:93.
35. Umar A, et al. Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst 2004, 96:261.
36. Weiderpass E, Adami HO, Baron JA, et al. Risk of endometrial cancer following estrogen replacement with and without progestins. J Natl Cancer Inst 1999, 91:1131.
37. Abu-Rustum NR, Gomez JD, Alektiar KM, et al. The incidence of isolated paraaortic nodal metastasis in surgically staged endometrial cancer patients with negative pelvic lymph nodes. Gynecol Oncol 2009, 115:236.
38. Ambros RA, Kurman RJ Identification of patients with stage I uterine endometrial adenocarcinoma at high risk of recurrence by DNA ploidy myometrial invasion and vascular invasion. Gynecol Oncol 1992, 45:235.
39. American College of Obstetricians and Gynecologists The role of transvaginal ultrasonography in the evaluation of postmenopausal bleeding. ACOG Committee Opinion No. 440. Obstet Gynecol 2009, 114:409.
40. Ayhan A, Turner R, Turner ZS, et al. Correlation between clinical and histopathologic risk factors; i.e., lymph node metastasis in early endometrial cancer. Int J Obstet Gynecol 1994, 4:306.
41. Baak JPA, Snijders WP, Van Diest PJ, et al. Confirmation of the prognostic value of the ECPI-1 score in FIGO stage I endometrial cancer patients with long follow up. Int J Gynecol Cancer 1995, 5:112.
42. Boruta DM, Gehrig PA, Nickles Fader A, et al. Management of women with uterine papillary serous cancer: a Society of Gynecologic Oncology (SGO) review. Gynecol Oncol 2009, 115:142.
43. Bourne TH, Campbell S, Steer CV, et al. Detection of endometrial cancer by transvaginal ultrasonography with color flow imaging and blood flow analysis. Gynecol Oncol 1991, 40:253.
44. Bristow RE, Zahurak ML, Alexander CJ, et al. FIGO stage IIIC endometrial carcinoma: resection of macroscopic nodal disease and other determinants of survival. Int J Gynecol Cancer 2003, 13:664.
45. Britton LC, Wilson TO, Gaffey TA, et al. DNA ploidy in endometrial carcinoma: major objective prognostic factor. Mayo Clin Proc 1990, 65:643.
46. Bryant MK, Dickinson A, Kehoe HK, et al: Lymphadenectomy for the management of endometrial cancer. Cochrane Database of Systematic Reviews 2010, Issue 1. Art. No.: CD007585. DOI: 10.1002/14651858.CD007585.pub2.
47. Cacciatore B, Lehtovirta P, Wahlstrom T, et al. Preoperative sonographic evaluation of endometrial cancer. Am J Obstet Gynecol 1989, 160:133.
48. Chan JK, Loizzi V, Youssef M, et al. Significance of comprehensive surgical staging in noninvasive papillary serous carcinoma of the endometrium. Gynecol Oncol 2003, 90:181.
49. Clark T, Barton P, Coomarasamy A, Gupta J, Khan K Investigating postmenopausal bleeding for endometrial cancer: cost-effectiveness of initial diagnostic strategies. BJOG 2006, 113:502.
50. Clark TJ, Voit D, Gupta JK, et al. Accuracy of hysteroscopy in the diagnosis of endometrial cancer and hyperplasia a systematic quantitative review. JAMA 2002, 288:1610.
51. Cohn DE, Horowitz NS, Mutch DG, Kim SM, Manolitsas T, Fowler JM Should the presence of lymphvascular space involvement be used to assign patients to adjuvant therapy following hysterectomy for unstaged endometrial cancer?. Gynecologic Oncology 2002, 87:243. Dec. UI: 12468320.
52. Connell PP, Rotmensch J, Waggoner S, Mundt AJ Significance of adnexal involvement in endometrial carcinoma. Gynecol Oncol 1999, 74:74.
53. Creasman W Revised FIGO staging for carcinoma of the endometrium. Int J Gynaecol Obstet 2009 May, 105(2):109.
54. Creasman WT, et al. Influence of cytoplasmic steroid receptor content on prognosis of early stage endometrial carcinoma. Am J Obstet Gynecol 1985, 151:922.
55. Creasman WT, DiSaia PJ, Blessing J Prognostic significance of peritoneal cytology in patients with endometrial cancer and preliminary data concerning therapy with intraperitoneal radiopharmaceuticals. Am J Obstet Gynecol 1981, 141:921.
56. Creasman WT, Kohler MF, Odicino F, et al. Prognosis of papillary serous, clear cell, and grade 3 stage I carcinoma of the endometrium. Gynecol Oncol 2004, 95:593.
57. Creasman WT, McCarty KS, McCarty KS Clinical correlation of estrogen, progesterone binding proteins in human endometrial adenocarcinoma. Obstet Gynecol 1980, 55:363.
58. Creasman WT, Morrow CP, Bundy BN, et al. Surgical pathologic spread patterns of endometrial cancer: a Gynecologic Oncology Group study. Cancer 1987, 60:2035.
59. Creasman WT, Rutledge FN The prognostic value of peritoneal cytology in gynecologic malignant disease. Am J Obstet Gynecol 1971, 110:773.
60. Creasman WT, DeGeest K, DiSaia PJ, Zaino RJ Significance of true surgical pathologic staging: a Gynecologic Oncology Group Study. American Journal of Obstetrics & Gynecology 1999, 181(1):31.
61. Dasarahally S, Mohan MA, Samuels MA, et al. Long-term outcomes of therapeutic pelvic lymphadenectomy for stage i endometrial adenocarcinoma. Gynecol Oncol 1998, 70:165.
62. Dijkhuizen FP, et al. The accuracy of endometrial sampling in the diagnosis of patients with endometrial carcinoma and hyperplasia: a meta-analysis. Cancer 2000, 89:1765.
63. DiSaia PJ, et al. Risk factors in recurrent patterns in stage I endometrial carcinoma. Am J Obstet Gynecol 1985, 151:1009.
64. Dotters DJ Preoperative CA125 in endometrial cancer. Is it useful?. Am J Obstet Gynecol 2000, 182:1328.
65. Eltabbakh GH, Moore AD Survival of women with surgical stage II endometrial cancer. Gynecol Oncol 1999, 74:80.
66. Feldman S, Cook EF, Harlow BL, Berkowitz RS Predicting endometrial cancer among older women who present with abnormal vaginal bleeding. Gynecol Oncol 1995, 56:376.
67. Giatromanolaki A, Sivridis E, Brekken R, et al. The angiogenic "vascular endothelial growth factor/flk-1(KDR) receptor" pathway in patients with endometrial carcinoma prognostic and therapeutic implications. Cancer 2001, 92:2569.
68. Giusa-Chiferi MG, Goncalves WJ, Baracat EC, et al. Transvaginal ultrasound, uterine biopsy and hysteroscopy for postmenopausal bleeding. Int J Gynaecol Obstet 1996, 55:39.
69. Goff BA, Kato D, Schmidt RA, et al. Uterine papillary serous carcinoma: patterns of metastatic spread. Gynecol Oncol 1994, 54:264.
70. Goldchmit R, Katz Z, Blickstein I, et al. The accuracy of endometrial Pipelle sampling with or without sonographic measurement of endometrial thickness. Obstet Gynecol 1993, 82:727.
71. Goldstein SR Unusual ultrasound appearance of the uterus in patients receiving tamoxifen. Am J Obstet Gynecol 1994, 170:447.
72. Gordon AN, Fleischer AC, Dudley BS, et al. Preoperative assessment of myometrial invasion of endometrial adenocarcinoma by ultrasound and MRI. Gynecol Oncol 1989, 34:175.
73. Granberg S, Wikland M, Karlson B, et al. Endometrial thickness as measured by endovaginal ultrasound for identifying endometrial abnormality. Am J Obstet Gynecol 1991, 164:47.
74. Grice J, Ek M, Greer B, et al. Uterine papillary serous carcinoma: evaluation of long-term survival in surgically staged patients. Gynecol Oncol 1998, 69:69.
75. Grimshaw RN, Tupper WC, Fraser RC, et al. Prognostic value of peritoneal cytology in endometrial carcinoma. Gynecol Oncol 1990, 36:97.
76. Hanson NB, et al. Prognostic significance of lymph-vascular space invasion in stage I endometrial cancer. Cancer 1985, 55:1753.
77. Havrilesky LJ, Alvarez Secord A, Bae-Jump V, et al. Outcomes in surgical stage I uterine papillary serous carcinoma. Gynecol Oncol 2007, 105:677.
78. Havrilesky LJ, Cragun JM, Calingaert B, et al. The prognostic significance of positive peritoneal cytology and adnexal/serosal metastasis in stage IIIA endometrial cancer. Gynecol Oncol 2007, 104:401.
79. Havrilesky LJ, Cragun JM, Calingaert B, et al. Resection of lymph node metastases influences survival in Stage III endometrial cancer. Gynecol Oncol 2005, 99:689.
80. Huang Y-W, Liu JC, Deatherage DE, et al. Epigenetic repression of microRNA-129-2 leads to overexpression of SOX4 oncogene in endometrial cancer. Cancer Res 2009, 69:9038.
81. Huang Y-W, Luo J, Weng Y-I, et al. Promoter hypermethylation of CIDEA, HAAO and RXFP3 associated with microsatellite instability in endometrial carcinomas. Gynecol Oncol 2010, 117:239.
82. Huh WK, Powell M, Leath CA, et al. Uterine papillary serous carcinoma: comparisons of outcomes in surgical stage I patients with and without adjuvant therapy. Gynecol Oncol 2003, 91:470.
83. Kadar N, Homesley HD, Malfetano JH Prognostic factors in surgical stage III and IV carcinoma of the endometrium. Obstet Gynecol 1994, 84:983.
84. Kadar N, Malfetano JH, Homesley HD Determinants of survival of surgically staged patients with endometrial carcinoma histologically confined to the uterus. Obstet Gynecol 1992, 80:655.
85. Kauppila A Oestrogen and progestin receptors as prognostic indicators in endometrial cancer. Acta Oncol 1989, 28:561.
86. Kilgore LC, Partridge EE, Alvarez RD, et al. Adenocarcinoma of the endometrium: survival comparisons of patients with and without pelvic node sampling. Gynecol Oncol 1995, 56:29.
87. Konski A, Poulter C, Keys H, et al. Absence of prognostic significance, peritoneal dissemination and treatment advantage in endometrial cancer patients with positive peritoneal cytology. Int J Radiat Oncol Biol Phys 1988, 4:49.
88. Lancaster JM, Powell CB, Kauff ND, et al. Society of Gynecologic Oncologists Education Committee. Society of Gynecologic Oncologists Education Committee statement on risk assessment for inherited gynecologic cancer predispositions. Gynecol Oncol 2007, 107:159.
89. Langer RD, Pierce JJ, O'Hanlan KA, et al. Transvaginal ultrasonography compared with endometrial biopsy for the detection of endometrial disease. N Engl J Med 1997, 337:1792.
90. Leitao MM, et al. Comparison of D&C and office endometrial biopsy accuracy in patients with FIGO grade 1 endometrial adenocarcinoma. Gynecol Oncol 2009, 113:105.
91. Levenback C, Burke TW, Silva E, et al. Uterine papillary serous carcinoma treated with PAC. Gynecol Oncol 1992, 46:317.
92. Lo SST, Cheng DKL, Ng TY, et al. The prognostic significance of positive peritoneal cytology in endometrial cancer. Int J Gynecol Cancer 1996, 6:473.
93. Lurain JR, Rice BL, Rademaker AW, et al. Prognostic factors associated with recurrence in clinical stage I adenocarcinoma. Obstet Gynecol 1991, 78:63.
94. Lurain JR, Rumsey NK, Schink JC, et al. Prognostic significance of positive peritoneal cytology in clinical stage I adenocarcinoma of the endometrium. Obstet Gynecol 1989, 74:175.
95. Lutz MH, et al. Endometrial carcinoma: a new method of classification of therapeutic and prognostic significance. Gynecol Oncol 1978, 6:83.
96. Mariani A, Dowdy S, Cliby WA, et al. Prospective assessment of lymphatic dissemination in endometrial cancer: a paradigm shift in surgical staging. Gynecol Oncol 2008, 109:11.
97. Mariani A, Webb MJ, Keeney G, et al. Stage IIIC endometrioid corpus cancer includes distinct subgroups. Gynecol Oncol 2002, 87:112.
98. Mariani A, Webb MJ, Keeney GL, Haddock MG, Calori G, Podratz KC Low-risk corpus cancer: is lymphadenectomy or radiotherapy necessary?. Am J Obstet Gynecol 2000, 182:1506.
99. Mariani A, Webb MJ, Galli L, Podratz KC Potential therapeutic role of para-aortic lymphadenectomy in node-positive endometrial cancer. Gynecol Oncol 2000, 348.
100. Matsushima-Nishiu M, Unoki M, Ono K, et al. Growth and gene expression profile analyses of endometrial cancer cells expressing exogenous PTEN. Cancer Res 2001, 61:3741.
101. Matthews RP, Hutchinson-Colas J, Maiman M, et al. Papillary serous and clear cell type lead to poor prognosis of endometrial carcinoma in black women. Gynecol Oncol 1997, 65:265.
102. McMeekin DS, Lashbrook D, Gold M, et al. Analysis of FIGO Stage IIIc endometrial cancer patients. Gynecol Oncol 2001, 81:273.
103. Milosevic MF, Dembo AD, Thomas GM Clinical significance of malignant peritoneal cytology in stage I endometrial carcinoma. Int J Gynecol Cancer 1992, 2:225.
104. Morrow CP, Bundy BN, Kurman RJ, et al. Relationship between surgical pathological risk factors and outcome in clinical stage I and II carcinoma of the endometrium. Gynecol Oncol 1991, 40:55.
105. Mutter GL, Lin MC, Fitzgerald JT, et al. Altered PTEN expression as a diagnostic marker for the earliest endometrial precancers. J Natl Cancer Inst 2000, 92:924.
106. Nickles Fader A, Starks D, Gehrig PA, et al. An updated clinicopatholgic study of early-stage uterine papillary serous carcinoma (UPSC). Gynecol Oncol 2009, 115:244.
107. Nordström B, Strang P, Lindgren A, et al. Endometrial carcinoma: the prognostic impact of papillary serous carcinoma (UPSC) in relation to nuclear grade, DNA ploidy and p53 expression. Anticancer Res 1996, 16:899.
108. Onda T, Yeshikawa H, Mizutani K, et al. treatment of node positive endometrial cancer with complete node dissection, chemotherapy and radiation therapy. Br J Cancer 1997, 75:183.
109. Onsrud N, et al. Endometrial carcinoma with cervical involvement (stage II): prognostic factors in value of combined radiological surgical treatment. Gynecol Oncol 1982, 13:76.
110. Panici PB, Basile S, Maneschi F, et al. Systematic pelvic lymphadenectomy vs no lymphadenectomy in early-stage endometrial carcinoma: randomized clinical trial. JNCI 2008, 100:1707.
111. Pfisterer J, Kommoss F, Sauerbrei V, et al. Prognostic value of DNA ploidy and S-phase fraction in stage I endometrial carcinoma. Gynecol Oncol 1995, 58:149.
112. Pisani A, Barbuto DA, Chen D, et al. HER-2/neu, p53, and DNA analysis as prognosticators for survival in endometrial carcinoma. Obstet Gynecol 1995, 85:729.
113. Podratz KC, Mariani A, Webb MJ Staging and therapeutic value of lymphadenectomy in endometrial cancer. Gynecol Oncol 1998, 70:163.
114. Podratz KC, Wilson TO, Gaffey TA, et al. DNA analysis facilitates the pretreatment identification of high-risk endometrial cancer patients. Am J Obstet Gynecol 1993, 168:1206.
115. Pollow K, Manz B, Grill JH Estrogen progesterone receptors in endometrial carcinoma. Steroids and Endometrial Cancer 1989, 101. Raven Press, New York. V.M. Jasonni (Ed.).
116. Quinn MA, Couchi M, Fortune V Endometrial carcinoma: steroid receptors and response to medroxyprogesterone acetate. Gynecol Oncol 1985, 21:314.
117. Smith RA, Cokkinides V, Brooks D, et al. Cancer screening in the United States, 2010: a review of current American Cancer Society guidelines and issues in cancer screening. CA Cancer J Clin 2010, 60:99.
118. Rosenberg P, Boeryd B, Simonsen E A new aggressive treatment approach to high grade endometrial cancer of possible benefit to patients with stage I uterine papillary cancer. Gynecol Oncol 1993, 48:32.
119. Rutledge FN The role of radical hysterectomy in adenocarcinoma of the endometrium. Gynecol Oncol 1974, 2:331.
120. Saga Y, Imai M, Jobo T, et al. Is peritoneal cytology a prognostic factor of endometrial cancer confined to the uterus?. Gynecol Oncol 2006, 103:277.
121. Schink JC, et al. Tumor size in endometrial cancer: a prospective factor for lymph node metastases. Obstet Gynecol 1987, 70:216.
122. Seamon LG, Bryant SA, Rheaume PS, et al. Comprehensive surgical staging for endometrial cancer in obese patients: comparing robotics and laparotomy. Obstet Gynecol 2009, 114:16.
123. Sherman ME, Sturgeon S, Brinton LA, et al. Risk factors and hormone levels in patients with serous and endometrioid uterine carcinomas. Mod Pathol 1997, 10:963.
124. Smith SM, Hoffman MS The role of vaginal hysterectomy in the treatment of endometrial cancer. AJOG 2007, 197:202.e1.
125. Smith-Bindman R, Kerlikowske K, Feldstein VA, et al. Endovaginal ultrasound to exclude endometrial cancer and other endometrial abnormalities. JAMA 1998, 280:1510.
126. Soper JT, et al. Intraperitoneal chromic phosphate P-32 suspension therapy in malignant peritoneal cytology and endometrial carcinoma. Am J Obstet Gynecol 1985, 153:191.
127. Sorbe B, Risberg B, Thonthwaite J Nuclear morphometry and DNA flow cytometry as prognostic methods for endometrial carcinoma. Int J Gynecol Cancer 1994, 4:94.
128. Stovall TG, Photopulos GJ, Poston WM, et al. Pipelle endometrial sampling in patients with known endometrial carcinoma. Obstet Gynecol 1991, 77:954.
129. Susini T, Rapi S, Savino L, et al. Prognostic value of flow cytometric deoxyribonucleic acid in endometrial carcinoma: comparison with other clinical-pathologic parameters. Am J Obstet Gynecol 1994, 170:527.
130. Takeshima N, Hirai Y, Yano K, et al. Ovarian metastasis in endometrial carcinoma. Gynecol Oncol 1998, 70:183.
131. Thornton JE, Ali S, O'Donovan P, et al. Flow cytometric studies of ploidy and proliferative indices in the Yorkshire trial of adjuvant progestogen treatment of endometrial cancer. Br J Obstet Gynaecol 1993, 100:253.
132. Todo Y, Kato H, Kaneuchi M, et al. Survival effect of para-aortic lymphadenectomy in endometrial cancer (SEPAL study): a retrospective cohort analysis. Lancet 2010, 375:1165.
133. Trimble EL, Kosary C, Park RC Lymph node sampling and survival in endometrial cancer. Gynecol Oncol 1998, 71:340.
134. Turner DA, Gershenson DM, Atkinson N, et al. The prognostic significance of peritoneal cytology for stage I endometrial cancer. Obstet Gynecol 1989, 74:775.
135. Varner RE, Sparks JM, Cameron CD, et al. Transvaginal sonography of the endometrium in postmenopausal women. Obstet Gynecol 1991, 78:195.
136. Veljovich DS, Paley PJ, Drescher CW, et al. Robotic surgery in gynecologic oncology: program initiation and outcomes after the first year with comparison with laparotomy for endometrial cancer staging. AJOG 2008, 198:679.e1.
137. Walker JL, Piedmonte MR, Spirtos NM, et al. Laparoscopy compared with laparotomy for comprehensive surgical staging of uterine cancer: gynecologic Oncology Group Study LAP2. J Clin Oncol 2009, 27:5331.
138. Wang J, Wieslander C, Hansen G, Cass I, Vasilev S, Holschneider CH Thin endometrial echo complex on ultrasound does not reliably exclude type 2 endometrial cancers. Gynecol Oncol Apr 2006, 101(1):120.
139. Weber AM, Belinson JL, Bradley LD, Piedmonte MR Vaginal ultrasonography versus endometrial biopsy in women with postmenopausal bleeding. Am J Obstet Gynecol 1997, 177:924.
140. Wethington SL, Barrena Medel NI, Wright JD, et al. Prognostic significance and treatment implications of positive peritoneal cytology in endometrial adenocarcinoma: unraveling a mystery. Gynecol Oncol 2009, 115:18.
141. Yazigi R, Piver MS, Blumenson L Malignant peritoneal cytology as prognostic indicator in stage I endometrial cancer. Obstet Gynecol 1983, 62:359.
142. Abeler UA, Kjorstad KE Endometrial adenocarcinoma with squamous cell differentiation. Cancer 1992, 69:488.
143. Alberhasky RC, Connely PJ, Christopherson WN Carcinoma of the endometrium. IV: mixed adenosquamous carcinoma. Am J Clin Pathol 1982, 77:655.
144. Aozasa K, Saeki K, Ohasawa M, et al. Malignant lymphoma of the uterus. Cancer 1993, 72:1959.
145. Benedetti-Panici P, Maneschi F, Cutillo G, et al. Anatomical and pathological study of retroperitoneal nodes in endometrial cancer. Int J Gynecol Cancer 1998, 8:322.
146. Chambers JT, Merino M, Kohorn EI, et al. Uterine papillary serous carcinoma. Obstet Gynecol 1987, 69:109.
147. Chen JL, Trost DC, Wilkinson EJ Endometrial papillary carcinoma: two clinical pathological types. Int J Gynecol Pathol 1985, 4:279.
148. Christopherson WN, Alberhasky RC, Connely PJ Carcinoma of the endometrium. I: a clinicopathological study of clear cell carcinoma and secretory carcinoma. Cancer 1982, 49:1511.
149. Christopherson WN, Alberhasky RC, Connely PJ Carcinoma of the endometrium. II: papillary adenocarcinoma: a clinico-pathological study of 46 patients. Am J Clin Pathol 1982, 77:534.
150. Connely PJ, Alberhasky RC, Christopherson WN Carcinoma of the endometrium. III: analysis of 865 cases of adenocarcinoma and adenocanthoma. Obstet Gynecol 1982, 59:569.
151. Eifel P, Hendrickson M, Ross J, et al. Simultaneous presentation of carcinoma involving the ovary and uterine corpus. Cancer 1982, 50:163.
152. Gitsch G, Friedlander ML, Wain GV, et al. Uterine papillary serous carcinoma. Cancer 1995, 75:2239.
153. Goff BA, Kato D, Schmidt RA, et al. Uterine papillary serous carcinoma: patterns of metastatic spread. Gynecol Oncol 1994, 54:264.
154. Hendrickson MR, Longacre TA, Kempson RL Uterine papillary serous carcinoma revisited. Gynecol Oncol 1991, 54:261.
155. Hendrickson MR, Ross J, Eifel PJ, et al. Adenocarcinoma of the endometrium: analysis of 256 cases of carcinoma limited to the uterine corpus. Gynecol Oncol 1982, 13:373.
156. Jeffrey JF, Krepart GV, Lotocki RJ Papillary serous adenocarcinomas of the endometrium. Obstet Gynecol 1986, 67:670.
157. Kaku T, Tsukamoto N, Hachisuga T, et al. Endometrial carcinoma associated with hyperplasia. Gynecol Oncol 1996, 60:22.
158. Klein Z, Markovitch O, Altaras M, et al. Advanced endometrial adenocarcinoma following endometrial ablation: a case report and review of the literature. Int J Gynecol Cancer 1997, 7:163.
159. Kurman RJ, Scully RE Clear cell carcinoma of the endometrium: analysis of 21 cases. Cancer 1976, 37:872.
160. Ng ABP, Reagan JW Incidence and prognosis of endometrial carcinoma by histologic grade and extent. Obstet Gynecol 1970, 35:437.
161. Ng ABP, et al. Mixed adenosquamous carcinoma of the endometrium. Am J Clin Pathol 1973, 59:765.
162. Parkash V, Carcangiu ML Uterine papillary serous carcinoma after radiation therapy for carcinoma of the cervix. Cancer 1992, 69:496.
163. Photopulos GJ, et al. Clear cell carcinoma of the endometrium. Cancer 1979, 43:1448.
164. Salazar OM, et al. Adenosquamous carcinoma of the endometrium. Cancer 1977, 40:119.
165. Schwartz Z, Ohel G, Birkenfeld A, et al. Second primary malignancy in endometrial carcinoma patients. Gynecol Oncol 1985, 22:40.
166. Silverberg SG, Bolin MG, DeGiorgi LS Adenoacanthoma and mixed adenosquamous carcinoma of the endometrium. Cancer 1972, 30:1307.
167. Silverberg SG, DeGiorgi LS Clear cell carcinoma of the endometrium: clinical-pathological and ultra-structural findings. Cancer 1973, 31:1127.
168. Sivridis E, Fox H, Buckley CH Endometrial carcinoma: two or three entities?. Int J Gynecol Cancer 1998, 8:183.
169. Umpierre SA, Burke TW, Tornos C, et al. Immunocytochemical analysis of uterine papillary serous carcinomas for estrogen and progesterone receptors. Int J Gynecol Pathol 1994, 13:127.
170. Zaino RJ, Kurtman R, Herbald D, et al. The significance of squamous differentiation. Cancer 1991, 68:2293.
171. Zaino RJ, Unger ER, Whitney C Synchronous carcinomas of the uterine corpus and ovary. Gynecol Oncol 1984, 19:329.
172. Arneson A Clinical results and histological changes following irradiation treatment of cancer of the corpus uteri. AJR 1936, 36:461.
173. Blake P, Swart AM, et al. Adjuvant external beam radiotherapy in the treatment of endometrial cancer (MRCASTEC and NCIC CTG EN.5 randomised trials): pooled trial results, systematic review,and meta-analysis. Lancet 2009, 373(9658):137. ASTEC/EN.5 Study Group.
174. Ball HG, Blessing JA, Lentz SS, et al. A phase II trial of paclitaxel in patients with advanced or recurrent adenocarcinoma of the endometrium: a Gynecologic Oncology Group study. Gynecol Oncol 1996, 62:278.
175. Barrena Medel NI, Bansal S, Miller DS, Wright JD, Herzog TJ Pharmacotherapy of endometrial cancer. Expert Opin Pharmaco 2009, 10:1939.
176. Behbakht K, Jordan EL, Casey C, et al. Prognostic indicators of survival in advanced endometrial cancer. Gynecol Oncol 1994, 55:363.
177. Benedetti Panici P, Basile S, Maneschi F, et al. Systematic pelvic lymphadenectomy versus no lymphadenectomy in early-stage endometrial carcinoma: randomized clinical trial. J Natl Cancer Inst 2008, 100:1707.
178. Ben-Shachar I, Pavelka J, Cohn DE, et al. Surgical staging for patients presenting with grade 1 endometrial carcinoma. Obstet Gynecol 2005, 105:487.
179. Chambers JT, Chambers SK, Kohorn EI, et al. Uterine papillary serous carcinoma treated with intraperitoneal cisplatin and intravenous doxorubicin and cyclophosphamide. Gynecol Oncol 1996, 60:438.
180. Chan JK, Cheung MK, Huh WK, et al. Therapeutic role of lymph node resection in endometrioid corpus cancer: a study of 12,333 patients. Cancer 2006, 107:1823.
181. Chan JK, Lin YG, Monk BJ, et al. Vaginal hysterectomy as primary treatment of endometrial cancer in medically compromised women. Obstet Gynecol 2001, 97(5 part 1):707.
182. Chen SS Operative treatment in stage I endometrial carcinoma with deep myometrial invasion and/or grade 3 tumor surgically limited to the corpus uteri: no recurrence with only primary surgery. Cancer 1989, 63:1843.
183. Chi DS, Welshinger M, Venkatraman ES, et al. The role of surgical cytoreduction in stage IV endometrial carcinoma. Gynecol Oncol 1997, 67:56.
184. Childers JM Laparoscopic lymph node sampling. Oper Tech Gynecol Surg 1996, 1:22.
185. Cliby WA, Clarke-Pearson DL, Dodge R, et al. Acute morbidity and mortality associated with selective pelvic and para-aortic lymphadenectomy in the surgical staging of endometrial adenocarcinoma. J Gynecol Tech 1995, 1:19.
186. COSA-NZ-UK Endometrial Cancer Study Groups Adjuvant medroxyprogesterone acetate in high risk endometrial cancer. Int J Gynecol Cancer 1998, 8:387.
187. COSA-NZ-UK Endometrial Cancer Study Groups Pelvic lymphadenectomy in high-risk endometrial cancer. Int J Gynecol Cancer 1996, 6:102.
188. Cragun JM, Havrilesky LJ, Calingaert B, et al. Retrospective analysis of selective lymphadenectomy in apparent early-stage endometrial cancer. J Clin Oncol 2005, 23:3668.
189. Creutzberg CL, van Putten WLJ, Koper PCM, et al. Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial. Lancet 2000, 355:1404.
190. Creutzberg CL, van Putten WLJ, Warlam-Rodenhuis CC, et al. Outcome of high-risk stage IC, grade 3, compared with stage I endometrial carcinoma patients: the postoperative radiation therapy in endometrial carcinoma trial. JCO 2004, 22:1234.
191. DeCruze SB, Green JA Hormone therapy in advanced and recurrent endometrial cancer: a systematic review. Int J Gynecol Cancer 2007, 17:964.
192. Dizon DS, Blessing JA, McMeekin DS, Sharma SK, DiSilvestro P, Alvarez RD Phase II trial of ixabepilone as second-line treatment in advanced endometrial cancer: gynecologic Oncology group trial 129P. J Clin Oncol 2009, 27:3104.
193. Elliott P, Green D, Coates M, et al. The efficacy of postoperative vaginal irradiation in preventing vaginal recurrence in endometrial cancer. Int J Gynecol Cancer 1994, 4:84.
194. Fanning J, Firestein S Prospective evaluation of the morbidity of complete lymphadenectomy in endometrial cancer. Int J Gynecol Cancer 1998, 8:270.
195. Fanning J, Piver MS Serial CA125 levels during chemotherapy for metastatic or recurrent endometrial cancer. Obstet Gynecol 1991, 77:278.
196. Fleming GF, Brunetto VL, Cella D, et al. Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a Gynecologic Oncology Group Study. J Clin Oncol 2004, 22:2159.
197. Fleming GF, Filiaci VL, Bentley RC, et al. Phase III randomized trial of doxorubicin + cisplatin versus doxorubicin + 24-h paclitaxel + filgrastim in endometrial carcinoma: a Gynecologic Oncology Group study. Ann Oncol 2004, 15:1173.
198. Greven K, Winter K, Underhill K, et al. Final analysis of RTOG 9708: adjuvant postoperative irradiation combined with cisplatin/paclitaxel chemotherapy following surgery for patients with high-risk endometrial cancer. Gynecol Oncol 2006, 103:155.
199. Hogberg T, et al. A randomized phase-III study on adjuvant treatment with radiation (RT) ± chemotherapy (CT) in early stage high-risk endometrial cancer (NSGO-EC-9501/EORTC 55991). J Clin Oncol 2007, 25(18S [abstact 5503]).
200. Homesley HD, et al. A randomized phase III trial in advanced endometrial carcinoma of surgery and volume directed radiation followed by cisplatin and doxorubicin with or without paclitaxel: a Gynecologic Oncology Group study. Gynecol Oncol 2009, 112:543.
201. Huh WK, Straughn JM, Mariani A, et al. Salvage of isolated vaginal recurrences in women with surgical stage I endometrial cancer: a multiinstitutional experience. Int J Gynecol Cancer 2007, 17:886.
202. Huh WK, Straughn JM, Mariani A, et al. Salvage of isolated vaginal recurrences in women with surgical stage I endometrial cancer: a multiinstitutional experience. Int J Gynecol Cancer 2007, 17:886.
203. Kauppila A Progestin therapy of endometrial, breast, and ovarian carcinoma. Acta Obstet Gynecol Scand 1984, 63:441.
204. Keys HM, Roberts JA, Brunetto VL, et al. A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 2004, 92:744.
205. Kilgore LC, Partridge EE, Alvarez RD, et al. Adenocarcinoma of the endometrium: survival comparison of patients with and without pelvic node sampling. Gynecol Oncol 1995, 56:26.
206. Kistner RW The effects of progesteronal agents on hyperplasia and carcinoma in situ of the endometrium. Int J Gynaecol Obstet 1970, 8:561.
207. Kitchener H, Swart AM, Qian Q, et al. Efficacy of systematic pelvic lymphadenectomy in endometrial cancer (MRC ASTEC trial): a randomised study. Lancet 2009, 373:125.
208. Kohorn EI Gestagens and endometrial carcinoma. Gynecol Oncol 1976, 4:398.
209. Kong AA, Johnson N, Cornes P, et al. Adjuvant radiotherapy for stage I endometrial cancer (Review). The Cochrane Library 2009, Issue 1.
210. Kornblith AB, Huang HQ, Walker JL, et al. Quality of life of patients with endometrial cancer undergoing laparoscopic International Federation of Gynecology and Obstetrics staging compared with laparotomy: a Gynecologic Oncology Group study. J Clin Oncol 2009, 27:5337.
211. Larson DM, Broste SK, Krawisz BR Surgery without radiotherapy for primary treatment of endometrial cancer. Obstet Gynecol 1998, 91:355.
212. Larson DM, Johnson K, Olson FA Pelvic and para-aortic lymphadenectomy for surgical staging of endometrial cancer: morbidity and mortality. Obstet Gynecol 1992, 79:998.
213. Leijon T, Rosenberg P, Boeryd B Total abdominal hysterectomy and bilateral salpingo-oophorectomy: a sufficient treatment for patients with low risk endometrial carcinoma. Int J Gynecol Oncol 1997, 7:376.
214. Lentz SS Advanced and recurrent endometrial carcinoma: hormonal therapy. Semin Oncol 1994, 21:100.
215. Lentz SS, Brady MF, Major FJ, et al. High-dose megestrol acetate in advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group study. J Clin Oncol 1996, 14:357.
216. Lewis GC, Slack NH, Mortel R, et al. Adjuvant progestogen therapy in primary definitive treatment of endometrial cancer. Gynecol Oncol 1974, 2:368.
217. Lin LL, Mutch DG, Rader JS, Powell MA, Grigsby PW External radiotherapy versus vaginal brachytherapy for patients with intermediate risk endometrial cancer. Gynecologic Oncology 2007, 106(1):215.
218. Lincoln S, Blessing JA, Lee RB, Rocereto TF Activity of paclitaxel as a second-line chemotherapy in endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 2003, 88:277.
219. Lowe MP, Johnson PR, Kamelle SC, et al. A multiinstitutional experience with robotic-assisted hysterectomy with staging for endometrial cancer. Obstet Gynecol 2009, 114(2 part 1):236.
220. Macdonald RR, Thorogood J, Mason MK A randomized trial of progestogens in the primary treatment of endometrial carcinoma. Br J Obstet Gynaecol 1988, 95:166.
221. Maggi R, Lissoni A, Spina F, et al. Adjuvant chemotherapy vs. radiotherapy in high-risk endometrial carcinoma: results of a randomized trial. Br J Cancer 2006, 2006(95):266.
222. Martin-Hirsch PL, Jarvis G, Kitchener H, Lilford R: Progestagens for endometrial cancer. Cochrane Database Syst Rev 2000;CD001040.
223. Massi G, Savino L, Susini T Vaginal hysterectomy versus abdominal hysterectomy for the treatment of stage I endometrial adenocarcinoma. Am J Obstet Gynecol 1996, 174:1320.
224. McMeekin DS, Filiaci VL, Thigpen JT, et al. The relationship between histology and outcome in advanced and recurrent endometrial cancer patients participating in first-line chemotherapy trials: a Gynecologic Oncology Group study. Gynecol Oncol 2007, 106:16.
225. Miller DS, Fleming G, Randall ME Chemo- and radiotherapy in adjuvant management of optimally debulked endometrial cancer. J Natl Compr Cancer Netw 2009 May, 7(5):535.
226. Mohan DS, Samuels MA, Selim MA, et al. Long-term outcomes of therapeutic pelvic lymphadenectomy for stage I endometrial adenocarcinoma. Gynecol Oncol 1998, 70:165.
227. Morris M, Alvarez RD, Kinney WK, Wilson TO Treatment of recurrent adenocarcinoma of the endometrium with pelvic exenteration. Gynecol Oncol 1996, 60:288.
228. Nout RA, Smit VTHBM, Putter H, et al. Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk (PORTEC-2): an open-label, non-inferiority, randomised trial. Lancet 2010, 375:816.
229. Nout RA, et al. Quality of life after pelvic radiotherapy or vaginal brachytherapy for endometrial cancer: first results of the randomized PORTEC-2 trial. J Clin Oncol 2009, 27:3547.
230. Orr JW, Holloway RW, Orr PF, Halimon JL Surgical staging of uterine cancer: an analysis of perioperative morbidity. Gynecol Oncol 1991, 42:209.
231. Pecorelli S (ed). FIGO annual report, years 1996-98, Int J Gynecol Obstet 79-118, 2003.
232. Podratz KC, Mariani A, Webb MJ Staging and therapeutic value of lymphadenectomy in endometrial cancer (Editorial). Gynecol Oncol 1998, 70:163.
233. Randall ME, et al. Randomized phase III trial of whole-abdominal irradiation versus doxorubicin and cisplatin chemotherapy in advanced endometrial carcinoma: a Gynecologic Oncology Group Study. J Clin Oncol 2006, 24:36.
234. Scholten AN, van Putten WLJ, Beerman H, et al. Postoperative radiotherapy for stage I endometrial carcinoma: long-term outcome of the randomized Portec Trial with central pathology review. Int J Radiation Oncol Biol Phys 2005, 63:834.
235. Selman AE, Fowler JM, Martinez-Monge R, Copeland LJ Doxorubicin and/or cisplatin based chemotherapy for the treatment of endometrial carcinoma with retroperitoneal lymph node metastases. Int J Gynecol Cancer 1998, 8:423.
236. Seski JC, et al. Adriamycin and cyclophosphamide chemotherapy for disseminated endometrial cancer. Obstet Gynecol 1981, 58:88.
237. Straughn JM, Huh WK, Kelly J, et al. Conservative management of stage I endometrial carcinoma after surgical staging. Gynecol Oncol 2002, 84:194.
238. Straughn JM, Huh WK, Orr JW, et al. Stage IC adenocarcinoma of the endometrium: survival comparisons of surgically staged patients with and without adjuvant radiation therapy. Gynecol Oncol 2003, 89:295.
239. Susumu N, Sagae S, Udagawa Y, et al. Randomized phase III trial of pelvic radiotherapy vs. cisplatin-based combined chemotherapy in patients with intermediate and high-risk risk endometrial carcinoma: a Japanese Gynecologic Oncology Group study. Gynecol Oncol 2008, 108:226.
240. Sutton G, Axelrod JH, Bundy BN, et al. Adjuvant whole abdominal irradiation in clinical stage I and II papillary serous or clear cell carcinoma of the endometrium: a phase II study of the Gynecologic Oncology Group. Gynecol Oncol 2006, 100:349.
241. Thigpen JT, et al. Phase II trial of Adriamycin in treatment of advanced or recurrent endometrial carcinoma. Cancer Treat Rep 1979, 63:21.
242. Thigpen JT, Blessing J, Homesley H, Creasman WT, Sutton G Phase II trial of cisplatin as first-line chemotherapy in patients with advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 1989, 33:68.
243. Thigpen JT, Blessing J, Lagasse LD, DiSaia PJ, Homesley HD A Phase II trial of cisplatin as second-line chemotherapy in patients with advanced or recurrent endometrial carcinoma. A Gynecologic Oncology Group Study. Am J Clin Oncol 1984, 3:253.
244. Thigpen JT, Blessing JA, DiSaia PJ, et al. A randomized comparison of doxorubicin alone versus doxorubicin plus cyclophosphamide in the management of advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group study. J Clin Oncol 1994, 12:1408.
245. Watanabe M, Aoki Y, Kase H, et al. Low risk endometrial cancer: a study of pelvic lymph node metastasis. Int J Gynecol Cancer 2003, 13:38.
246. Writing Committee on behalf of ASTEC Study Group: efficacy of systematic pelvic lymphadenectomy in endometrial cancer (MRC ASTEC trial): a randomised study. Lancet 2009, 373:125.
247. Zanetta G, Gabrielle GL, Cappellini A, Manggioni C Conservative management of endometrial carcinoma with prolonged preservation of the uterus in a young patient. Int J Gynecol Cancer 1997, 7:332.
248. Zanotti KM, Belinson JL, Kennedy AW, et al. The use of paclitaxel and platinum-based chemotherapy in uterine papillary serous carcinoma. Gynecol Oncol 1999, 74:272.